10x Genomics Q4 revenue up 18% to $184M but net loss widens to $49M; FY2024 guidance 8-12% growth

10x Genomics, Inc.

2023-FY EPS reported -$2.18 revenue$618,727,000

Q4 2023 revenue $184.0M (+18% YoY); FY2023 revenue $618.7M (+20% YoY).
Q4 gross margin 63% vs 76% YoY due to higher mix of Spatial instruments.
Q4 operating loss $55.2M (vs $23.1M), including $38.9M stock-based comp and $19.6M in-process R&D expense.
Full year 2023 net loss $255.1M, widened from $166.0M in 2022.
FY2024 revenue guidance $670M-$690M (8-12% growth); cumulative instruments sold reached 5,966.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.75

10x Genomics, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $184.0 million for the fourth quarter and $618.7 million for the full year of 2023, net income Net loss was $49.0 million for the fourth quarter of 2023, as compared to a net loss of $17.2 million for the correspond. Guidance initiated.

Period: fourth quarter and full year ended December 31, 2023
Revenue: $184.0 million for the fourth quarter and $618.7 million for the full year of 2023
Net income: Net loss was $49.0 million for the fourth quarter of 2023, as compared to a net loss of $17.2 million for the correspond
Guidance: initiated
Result: reported results

Exact text from the filing

10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

10x Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001770787-24-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.